Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Hanefeld
Markolf
M
Centre for Clinical Studies, Gesellschaft für Wissens-und Technologietransfer, Technical University Dresden, 01307 Dresden, Germany. hanefeld@gwtonline-zks.de
Forst
Thomas
T
D001559:Benzhydryl Compounds; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005960:Glucosides / Q000627:therapeutic use*; D006029:Glycosuria; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
D001559:Benzhydryl Compounds; D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin